Skip to main content

Table 5 Summary of demography and medication differences between participants treated with olanzapine monotherapy bearing the rs2011425 non-G allele and G allele

From: The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine

 rs2011425 T/Trs2011425 G/T, G/GP
Age (years)51.77 ± 15.2644.33 ± 14.080.064
Sex (male/female)7/1132/410.704
Smoking (Nonsmoker/smoker)17/167/60.704
BMI (kg/m2)24.12 ± 4.5323.60 ± 5.290.675
PANSS total score72.30 ± 16.7571.61 ± 12.850.871
Disease duration (years)19.86 ± 13.3117.83 ± 14.830.574
CPZeqa (mg/day)490.41 ± 245.61494.44 ± 260.030.951
BPDeqb (mg/day)0.81 ± 1.860.67 ± 1.570.766
DZPeqc (mg/day)7.97 ± 14.306.19 ± 9.190.953
  1. Data are presented as mean ± standard deviation values
  2. BMI Body mass index, PANSS Positive and Negative Syndrome Scale
  3. aThe daily dosages of antipsychotic drugs were converted to approximate chlorpromazine equivalents
  4. bThe daily dosages of anticholinergic antiparkinsonian drugs were converted to approximate biperiden equivalents
  5. cThe daily dosages of benzodiazepine were converted to approximate diazepam equivalents